TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32273256

Group type: EXPERIMENTAL
Intervention: SSN Imaging Reporting System (SSN‐IRS)
Number of subjects: 437
Study: 34735388

Group type: EXPERIMENTAL
Intervention: Total capture drape
Number of subjects: 68

Group type: COMPARATOR
Intervention: Standard drape
Number of subjects: 68
Study: 36202933

Group type: EXPERIMENTAL
Intervention: Half-dose photodynamic therapy (PDT)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Oral eplerenone
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Half-dose PDT (crossover treatment)
Number of subjects: 90
Study: 33986477

Group type: EXPERIMENTAL
Intervention: Darbepoetin alpha (Darbe) 10 μg/kg IV
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 32448782

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Tacrolimus (TAC)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF) and Tacrolimus (TAC)
Number of subjects: 150
Study: 35090087

Group type: EXPERIMENTAL
Intervention: 0.12% non-alcoholic chlorhexidine (CHX)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 2% saline rinses (NaCl)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Herbal mouthwash (MW)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Distilled water (H2O)
Number of subjects: 60
Study: 33432167

Group type: EXPERIMENTAL
Intervention: Botulinum neurotoxin (BNT) injections
Number of subjects: 100

Group type: COMPARATOR
Intervention: Surgical intervention (bimedial rectus muscle recession)
Number of subjects: 100
Study: 33751774

Group type: EXPERIMENTAL
Intervention: VisioCyt test
Number of subjects: 1360
Study: 33689989

Group type: EXPERIMENTAL
Intervention: Anteromedial hip musculature strengthening (AMHG)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Posterolateral hip musculature strengthening (PLHG)
Number of subjects: 52
Study: 33629751

Group type: EXPERIMENTAL
Intervention: Mental Habits (CBM intervention)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Symptom Tracking (Control)
Number of subjects: 40
Study: 32986235

Group type: EXPERIMENTAL
Intervention: Drug-coated balloons
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 0
Study: 34308814

Group type: COMPARATOR
Intervention: Yoga
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Memory Support System (MSS) training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Computerized cognitive training (CCT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Peer support group (SG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wellness education (WE)
Number of subjects: 0
Study: 34798475

Group type: EXPERIMENTAL
Intervention: Interdisciplinary teaching with creativity training for Group 2 (teaching assistants, n = 30)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Interdisciplinary teaching for Group 1 (typical students, n = 80)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Control group (n = 81) taught by nursing faculty only, without creativity training
Number of subjects: 191
Study: 33881402

Group type: EXPERIMENTAL
Intervention: Therapeutically purposeful use of smartphone
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Recreational use by the physiotherapist
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Recreational use by the patient
Number of subjects: 118

Group type: COMPARATOR
Intervention: No smartphone use (control condition)
Number of subjects: 118
Study: 32057627

Group type: EXPERIMENTAL
Intervention: Hand massage
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Foot massage
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo massage
Number of subjects: 90
Study: 34523382

Group type: EXPERIMENTAL
Intervention: Nebulised dexmedetomidine 2 μg/kg (group D)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Nebulised ketamine 2 mg/kg (group K)
Number of subjects: 71
Study: 32866050

Group type: EXPERIMENTAL
Intervention: 25% silver nitrate (AgNO3) solution followed by 5% sodium fluoride (NaF) varnish without fTCP
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: 25% silver nitrate (AgNO3) solution followed by 5% sodium fluoride (NaF) varnish with functionalized tricalcium phosphate (fTCP)
Number of subjects: 408
Study: 35099659

Group type: EXPERIMENTAL
Intervention: Anodal-tDCS
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Cathodal-tDCS
Number of subjects: 39

Group type: COMPARATOR
Intervention: Sham-tDCS
Number of subjects: 39

Group type: COMPARATOR
Intervention: No-tDCS
Number of subjects: 39
Study: 33191181

Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 30

Group type: COMPARATOR
Intervention: Tacrolimus
Number of subjects: 30
Study: 35394807

Group type: COMPARATOR
Intervention: Education arm
Number of subjects: 461

Group type: COMPARATOR
Intervention: Air filtration arm
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Exposure-response analysis
Number of subjects: 461
Study: 34181770

Group type: EXPERIMENTAL
Intervention: HVPG measurement after intervention
Number of subjects: 289

Group type: COMPARATOR
Intervention: HVPG measurement in compensated cirrhosis
Number of subjects: 289

Group type: COMPARATOR
Intervention: HVPG measurement in decompensated cirrhosis
Number of subjects: 289

Group type: COMPARATOR
Intervention: HVPG measurement in alcohol-associated cirrhosis
Number of subjects: 289

Group type: COMPARATOR
Intervention: HVPG measurement in unicentric trials
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Smallest detectable difference in HVPG
Number of subjects: 289
Study: 34578906

Group type: EXPERIMENTAL
Intervention: Cannabidiol supplementation (CBD)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 33318104

Group type: EXPERIMENTAL
Intervention: 2-hour simulation-based training session
Number of subjects: 57

Group type: COMPARATOR
Intervention: Wait list control condition
Number of subjects: 57
Study: 36238481

Group type: EXPERIMENTAL
Intervention: Serum M-CSF
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Serum TIMP-1
Number of subjects: 60

Group type: COMPARATOR
Intervention: Serum CER
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Serum levels of M-CSF, CER, TIMP-1, HA, PC-III, C-IV, and LN
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: M-CSF, TIMP-1, LN, HA, C-IV, and PC-III levels
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Correlation of liver fibrosis with serum M-CSF, PC-III, TIMP-1, HA, LN, and C-IV levels
Number of subjects: 60

Group type: COMPARATOR
Intervention: Correlation of liver fibrosis with serum CER
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Diagnostic usefulness of M-CSF, CER, and TIMP-1
Number of subjects: 60
Study: 32174356

Group type: EXPERIMENTAL
Intervention: Informative auditory cues on timing and direction of upcoming motion
Number of subjects: 20

Group type: COMPARATOR
Intervention: Non-informative auditory cues
Number of subjects: 20
Study: 35717771

Group type: EXPERIMENTAL
Intervention: Mindfulness (cognitive approach)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Sleep education
Number of subjects: 121

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 121
Study: 32222929

Group type: EXPERIMENTAL
Intervention: Health-related quality of life (HRQOL) assessment using SF-36 tool
Number of subjects: 500
Study: 34020153

Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic exercise (EX)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Light-intensity exercise control (CON)
Number of subjects: 35
Study: 32813928

Group type: EXPERIMENTAL
Intervention: Abdominal hypopressive technique (AHT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pelvic floor muscle training (PFMT)
Number of subjects: 0
Study: 33612294

Group type: EXPERIMENTAL
Intervention: Thoracic endovascular aortic repair for complicated acute type B aortic dissections
Number of subjects: 172

Group type: COMPARATOR
Intervention: Thoracic endovascular aortic repair for uncomplicated acute type B aortic dissections
Number of subjects: 172

Group type: COMPARATOR
Intervention: Complicated type B aortic dissections
Number of subjects: 172

Group type: COMPARATOR
Intervention: Uncomplicated acute type B aortic dissections
Number of subjects: 172
Study: 33191450

Group type: EXPERIMENTAL
Intervention: nab-paclitaxel plus S-1 (nab-P/S)
Number of subjects: 110

Group type: COMPARATOR
Intervention: nab-paclitaxel plus gemcitabine (nab-P/G)
Number of subjects: 110
Study: 32926799

Group type: EXPERIMENTAL
Intervention: Curcuma longa extract (CL)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 34600554

Group type: EXPERIMENTAL
Intervention: Preoperative and postoperative immunonutrition
Number of subjects: 164

Group type: COMPARATOR
Intervention: Standard nutrition
Number of subjects: 164

Group type: COMPARATOR
Intervention: EQ-5D-3L
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: QLU-C10D
Number of subjects: 164

Group type: COMPARATOR
Intervention: EQ-5D-3L anxiety
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Utility scores
Number of subjects: 164
Study: 33232476

Group type: EXPERIMENTAL
Intervention: Pacritinib 100 mg once per day
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Pacritinib 100 mg twice per day
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Pacritinib 200 mg twice per day
Number of subjects: 161
Study: 34698889

Group type: EXPERIMENTAL
Intervention: Atorvastatin (37.9% of participants)
Number of subjects: 5981

Group type: EXPERIMENTAL
Intervention: Simvastatin (29.6% of participants)
Number of subjects: 5981

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (25.5% of participants)
Number of subjects: 5981

Group type: EXPERIMENTAL
Intervention: Other statins (7.0%, predominantly pravastatin)
Number of subjects: 5981

Group type: EXPERIMENTAL
Intervention: High-potency statins (atorvastatin and rosuvastatin)
Number of subjects: 5981

Group type: COMPARATOR
Intervention: Low-/moderate-potency statins
Number of subjects: 5981
Study: 33716071

Group type: EXPERIMENTAL
Intervention: Sacrospinous hysteropexy with graft
Number of subjects: 183

Group type: COMPARATOR
Intervention: Vaginal hysterectomy with uterosacral ligament suspension
Number of subjects: 183
Study: 32827835

Group type: EXPERIMENTAL
Intervention: 4vHPV vaccine
Number of subjects: 1128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1128
Study: 35568261

Group type: EXPERIMENTAL
Intervention: Dermabond PRINEO
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Staples
Number of subjects: 54

Group type: COMPARATOR
Intervention: Dermabond
Number of subjects: 54
Study: 34929410

Group type: EXPERIMENTAL
Intervention: Seven-day course of antibiotics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fourteen-day course of antibiotics
Number of subjects: 0
Study: 36153529

Group type: EXPERIMENTAL
Intervention: Ensuring the availability of influenza vaccine supply
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Developing influenza vaccine awareness
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both ensuring influenza vaccine supply and developing influenza vaccine awareness
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control arm with no intervention
Number of subjects: 0
Study: 35724670

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg plus FDCSL (400/90 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lovastatin 40 mg plus FDCSL (400/90 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: FDCSL (400/90 mg) alone
Number of subjects: 12
Study: 32302321

Group type: EXPERIMENTAL
Intervention: High transparency modification in Experiment 2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard financial aid allocation task in Experiment 1
Number of subjects: 0
Study: 35085455

Group type: EXPERIMENTAL
Intervention: Multicomponent, family-based intervention including parent group sessions, home nursing visits, and multidisciplinary clinical encounters.
Number of subjects: 11

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Parent focus groups (qualitative assessment).
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Contextual factors identified by healthcare providers (HCPs).
Number of subjects: 11
Study: 34821105

Group type: EXPERIMENTAL
Intervention: 200 mg tangeretin orally for 4 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 24
Study: 35316078

Group type: EXPERIMENTAL
Intervention: UMP in modified flank free supine position (Group A)
Number of subjects: 122

Group type: COMPARATOR
Intervention: UMP in prone position (Group B)
Number of subjects: 122
Study: 35912663

Group type: EXPERIMENTAL
Intervention: Financial management intervention for people with HIV who are experiencing homelessness or housing instability
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Community-engaged approach to restarting research
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: COVID-19 policies and procedures developed for BAO
Number of subjects: 0
Study: 32567679

Group type: EXPERIMENTAL
Intervention: Resistance training (RES)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Endurance training (END)
Number of subjects: 84
Study: 35901954

Group type: EXPERIMENTAL
Intervention: PIP 10 cmH2O
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: PIP 15 cmH2O
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: PIP 20 cmH2O
Number of subjects: 108
Study: 33115783

Group type: EXPERIMENTAL
Intervention: Resistant starch and/or polydextrose (PD) supplementation for 50 days
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Polydextrose (PD) supplementation
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Higher E‐DII scores
Number of subjects: 75
Study: 32951708

Group type: EXPERIMENTAL
Intervention: Eugenol nanoemulsion gel 4%
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 68
Study: 35144947

Group type: EXPERIMENTAL
Intervention: Personal Energy Planning (PEP) programme, a tailored, web‐supported 7‐9 weeks energy management programme
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Personal Energy Planning (PEP) programme
Number of subjects: 30

Group type: COMPARATOR
Intervention: Attention control (general disease self‐management education)
Number of subjects: 30
Study: 33568616

Group type: EXPERIMENTAL
Intervention: WhatsApp group (n = 24)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (n = 19)
Number of subjects: 43
Study: 34133061

Group type: EXPERIMENTAL
Intervention: In-center nocturnal hemodialysis (INHD)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conventional hemodialysis
Number of subjects: 36
Study: 33418336

Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery (SRS) and Methotrexate (MTX)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Methotrexate (MTX)
Number of subjects: 128
Study: 35964610

Group type: EXPERIMENTAL
Intervention: Mepolizumab (40 mg for 6–11 years; 100 mg for 12–17 years)
Number of subjects: 290

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Mepolizumab
Number of subjects: 290
Study: 33090083

Group type: EXPERIMENTAL
Intervention: Group Intervention (GI)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Individual Intervention (II)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Standard Intervention (SI)
Number of subjects: 125
Study: 35768897

Group type: EXPERIMENTAL
Intervention: Wrist Position Sense Test (WPST) treatment group (n=10)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (n=7)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Wrist Position Sense Test (WPST) in children with CP
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Wrist Position Sense Test (WPST)
Number of subjects: 28
Study: 33719505

Group type: EXPERIMENTAL
Intervention: MitraClip treatment
Number of subjects: 614

Group type: COMPARATOR
Intervention: Guideline-directed medical therapy alone
Number of subjects: 614
Study: 32952830

Group type: EXPERIMENTAL
Intervention: 400μg sublingual Misoprostol
Number of subjects: 211

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 211
Study: 35728797

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: 200 IU/day vitamin D
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: 800 IU/day vitamin D
Number of subjects: 73
Study: 34399765

Group type: EXPERIMENTAL
Intervention: Quality of amenities in parks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diversity of active facilities in parks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Greenness of parks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Park safety in low-income neighbourhoods
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Park safety in high-income neighbourhoods
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Park aesthetics in low-income neighbourhoods
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Park aesthetics in high-income neighbourhoods
Number of subjects: 0
Study: 35034125

Group type: EXPERIMENTAL
Intervention: Target and distractor stimuli (differing in color)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Task‐irrelevant filler stimuli (having a third color)
Number of subjects: 0
Study: 32129145

Group type: EXPERIMENTAL
Intervention: Achillon
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: MMIR
Number of subjects: 114
Study: 36384662

Group type: EXPERIMENTAL
Intervention: Evolocumab (140 mg subcutaneous every 2 weeks)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 33742240

Group type: EXPERIMENTAL
Intervention: Dexamethasone premedication (8 mg/twice daily for 3 days) followed by tapering dexamethasone (4 mg/daily for 2 days followed by 2 mg/daily for 2 days)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Dexamethasone premedication (8 mg/twice daily for 3 days)
Number of subjects: 130
Study: 32367340

Group type: EXPERIMENTAL
Intervention: ezetimibe/rosuvastatin 10/5 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: rosuvastatin 20 mg
Number of subjects: 50
Study: 35729758

Group type: EXPERIMENTAL
Intervention: Ketogenic diet (KD) (∼25 g CHO/d)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Carbohydrate diet (CHO) (∼285 g CHO/d)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Ketogenic diet (KD)
Number of subjects: 8
Study: 34112100

Group type: EXPERIMENTAL
Intervention: Topical estrogen
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Topical testosterone
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Water-based intimate lubricant gel
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Vaginal dilators
Number of subjects: 195
Study: 33128480

Group type: EXPERIMENTAL
Intervention: c‐tPCS at 75 Hz
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: c‐tPCS at 4 Hz
Number of subjects: 15

Group type: COMPARATOR
Intervention: sham
Number of subjects: 15
Study: 36287636

Group type: EXPERIMENTAL
Intervention: PGT-A
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional IVF (Control)
Number of subjects: 0
Study: 33450831

Group type: EXPERIMENTAL
Intervention: Meditation program (4 weeks, 16 hours)
Number of subjects: 0
Study: 32575151

Group type: EXPERIMENTAL
Intervention: Virtual reality intervention (immersive video content as a distraction method)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 40
Study: 32706100

Group type: EXPERIMENTAL
Intervention: CPAP (n = 63)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control (nil intervention, n = 63)
Number of subjects: 126
Study: 35985037

Group type: EXPERIMENTAL
Intervention: 50000 IU/w vitamin D3 for 12 weeks
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: 50000 IU/w vitamin D3 for 12 weeks (second phase)
Number of subjects: 46
Study: 33694031

Group type: EXPERIMENTAL
Intervention: Ayahuasca (N = 14)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (N = 16)
Number of subjects: 30
Study: 36249225

Group type: EXPERIMENTAL
Intervention: Wristband tracker (Withings Pulse HR) for 3 weeks
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Thermometer patch (Tucky thermometer) for 3 weeks
Number of subjects: 150
Study: 35019120

Group type: EXPERIMENTAL
Intervention: Ringer Lactate (RL) group
Number of subjects: 80

Group type: COMPARATOR
Intervention: Physiologic Solution (PS) group
Number of subjects: 80
Study: 33321462

Group type: EXPERIMENTAL
Intervention: Panitumumab plus FOLFOX followed by maintenance with panitumumab
Number of subjects: 196

Group type: COMPARATOR
Intervention: Panitumumab + 5‐FU/LV
Number of subjects: 196

Group type: COMPARATOR
Intervention: Single-agent panitumumab
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Combination of PRESSING panel and response dynamics
Number of subjects: 196
Study: 33074769

Group type: EXPERIMENTAL
Intervention: Sustained Release (SR) tablets of isradipine composed of 15.0% (wt/wt) HPMC
Number of subjects: 0

Group type: COMPARATOR
Intervention: Immediate Release (IR) tablets of isradipine
Number of subjects: 0
Study: 33402409

Group type: EXPERIMENTAL
Intervention: Edoxaban (60 mg daily or 30 mg daily if patients had dose-reduction criteria)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Dual antiplatelet therapy (DAPT) using aspirin (100 mg daily) plus clopidogrel (75 mg daily) for 6 months
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 220

Group type: COMPARATOR
Intervention: DAPT
Number of subjects: 220
Study: 35905861

Group type: EXPERIMENTAL
Intervention: Kind acts for others
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Kind acts for themselves
Number of subjects: 182

Group type: COMPARATOR
Intervention: Control (listing daily activities)
Number of subjects: 182
Study: 33757537

Group type: EXPERIMENTAL
Intervention: Active tube clearance (ATC) using a 28F PleuraFlow device
Number of subjects: 520

Group type: COMPARATOR
Intervention: Standard drainage (conventional chest tube)
Number of subjects: 520
Study: 33293310

Group type: EXPERIMENTAL
Intervention: Hard physical work during early working life (standing/walking work with lifting/carrying)
Number of subjects: 5909

Group type: EXPERIMENTAL
Intervention: Hard physical work during early working life (heavy or fast work that is physically strenuous)
Number of subjects: 5909

Group type: COMPARATOR
Intervention: Sedentary work during early working life
Number of subjects: 5909
Study: 35718262

Group type: EXPERIMENTAL
Intervention: Delta variant group (vaccination period)
Number of subjects: 1121
Study: 34090987

Group type: EXPERIMENTAL
Intervention: Supervised exercise therapy (SET) 3× weekly for 6 months
Number of subjects: 210

Group type: COMPARATOR
Intervention: Control group (1× weekly health lectures)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Supervised exercise therapy (SET)
Number of subjects: 210